Ligands binding to the cellular prion protein induce its protective proteolytic release with therapeutic potential in neurodegenerative proteinopathies

The cellular prion protein (PrPC) is a central player in neurodegenerative diseases caused by protein misfolding, such as prion diseases or Alzheimer’s disease (AD). Expression levels of this GPI-anchored glycoprotein, especially at the neuronal cell surface, critically correlate with various pathomechanistic aspects underlying these diseases, such as templated misfolding (in prion diseases) and neurotoxicity and, hence, with disease progression and severity. In stark contrast to cell-associated PrPC, soluble extracellular forms or fragments of PrP are linked with neuroprotective effects, which is likely due to their ability to interfere with neurotoxic disease-associated protein conformers in the interstitial fluid. Fittingly, the endogenous proteolytic release of PrPC by the metalloprotease ADAM10 (‘shedding’) was characterized as a protective mechanism. Here, using a recently generated cleavage-site specific antibody, we shed new light on earlier studies by demonstrating that shed PrP (sPrP) negatively correlates with conformational conversion (in prion disease) and is markedly redistributed in murine brain in the presence of prion deposits or AD-associated amyloid plaques indicating a blocking and sequestrating activity. Importantly, we reveal that administration of certain PrP-directed antibodies and other ligands results in increased PrP shedding in cells and organotypic brain slice cultures. We also provide mechanistic and structural insight into this shedding-stimulating effect. In addition, we identified a striking exception to this, as one particular neuroprotective antibody, due to its special binding characteristics, did not cause increased shedding but rather strong surface clustering followed by fast endocytosis and degradation of PrPC. Both mechanisms may contribute to the beneficial action described for some PrP-directed antibodies/ligands and pave the way for new therapeutic strategies against devastating and currently incurable neurodegenerative diseases.

[1]  T. Nagao,et al.  Accumulation of cellular prion protein within β‐amyloid oligomer plaques in aged human brains , 2021, Brain pathology.

[2]  F. Bouwman,et al.  The coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer’s disease , 2020, Acta Neuropathologica.

[3]  M. Etzkorn,et al.  Clustering of human prion protein and α-synuclein oligomers requires the prion protein N-terminus , 2020, Communications Biology.

[4]  A. Aguzzi,et al.  Recent developments in antibody therapeutics against prion disease. , 2020, Emerging topics in life sciences.

[5]  G. Legname,et al.  Novel regulators of PrPC expression as potential therapeutic targets in prion diseases , 2020, Expert opinion on therapeutic targets.

[6]  B. Puig,et al.  Transgenic Overexpression of the Disordered Prion Protein N1 Fragment in Mice Does Not Protect Against Neurodegenerative Diseases Due to Impaired ER Translocation , 2020, Molecular Neurobiology.

[7]  S. Schreiber,et al.  Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints , 2020, bioRxiv.

[8]  M. Frosch,et al.  PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins , 2019, Acta Neuropathologica.

[9]  S. Edland,et al.  Shortening heparan sulfate chains prolongs survival and reduces parenchymal plaques in prion disease caused by mobile, ADAM10-cleaved prions , 2019, Acta Neuropathologica.

[10]  S. Schreiber,et al.  Antisense oligonucleotides extend survival of prion-infected mice , 2019, JCI insight.

[11]  M. Diamond,et al.  Propagation of Protein Aggregation in Neurodegenerative Diseases. , 2019, Annual review of biochemistry.

[12]  S. Schreiber,et al.  Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development , 2019, Proceedings of the National Academy of Sciences.

[13]  M. Z. Cader,et al.  Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers , 2019, The Journal of Biological Chemistry.

[14]  S. Strittmatter,et al.  Anti‐PrPC antibody rescues cognition and synapses in transgenic alzheimer mice , 2019, Annals of clinical and translational neurology.

[15]  S. Strittmatter,et al.  Systematic and standardized comparison of reported amyloid-β receptors for sufficiency, affinity, and Alzheimer's disease relevance , 2019, The Journal of Biological Chemistry.

[16]  C. Sigurdson,et al.  Cellular and Molecular Mechanisms of Prion Disease. , 2019, Annual review of pathology.

[17]  C. Dyer.  British man with CJD gets experimental treatment in world first , 2018, British Medical Journal.

[18]  M. Rowan,et al.  Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo , 2018, The Journal of Neuroscience.

[19]  M. Schweizer,et al.  Muskelin Coordinates PrPC Lysosome versus Exosome Targeting and Impacts Prion Disease Progression , 2018, Neuron.

[20]  S. Hornemann,et al.  A bispecific immunotweezer prevents soluble PrP oligomers and abolishes prion toxicity , 2018, bioRxiv.

[21]  K. Kirshenbaum,et al.  Anti-prion Protein Antibody 6D11 Restores Cellular Proteostasis of Prion Protein Through Disrupting Recycling Propagation of PrPSc and Targeting PrPSc for Lysosomal Degradation , 2018, Molecular Neurobiology.

[22]  M. Engelhard,et al.  Dimerization of the cellular prion protein inhibits propagation of scrapie prions , 2018, Journal of Biological Chemistry.

[23]  W. Jackson,et al.  Structural and mechanistic aspects influencing the ADAM10-mediated shedding of the prion protein , 2018, Molecular Neurodegeneration.

[24]  P. Saftig,et al.  In vivo regulation of the A disintegrin and metalloproteinase 10 (ADAM10) by the tetraspanin 15 , 2018, Cellular and Molecular Life Sciences.

[25]  V. Cecchetti,et al.  Pharmacological Agents Targeting the Cellular Prion Protein , 2018, Pathogens.

[26]  Jessica Siltberg-Liberles,et al.  Interaction of Peptide Aptamers with Prion Protein Central Domain Promotes α-Cleavage of PrPC , 2018, Molecular Neurobiology.

[27]  B. Caughey,et al.  A Promising Antiprion Trimethoxychalcone Binds to the Globular Domain of the Cellular Prion Protein and Changes Its Cellular Location , 2017, Antimicrobial Agents and Chemotherapy.

[28]  P. Saftig,et al.  The metalloproteinase ADAM10: A useful therapeutic target? , 2017, Biochimica et biophysica acta. Molecular cell research.

[29]  P. Saftig,et al.  Diverse functions of the prion protein - Does proteolytic processing hold the key? , 2017, Biochimica et biophysica acta. Molecular cell research.

[30]  I. Zerr,et al.  α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B , 2017, Nature Neuroscience.

[31]  R. Nonno,et al.  An antipsychotic drug exerts anti-prion effects by altering the localization of the cellular prion protein , 2017, PloS one.

[32]  David W. Colby,et al.  The N-terminus of the prion protein is a toxic effector regulated by the C-terminus , 2017, eLife.

[33]  V. Daggett,et al.  Simulations of membrane‐bound diglycosylated human prion protein reveal potential protective mechanisms against misfolding , 2017, Journal of neurochemistry.

[34]  W. Surewicz,et al.  Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease , 2016, Neurobiology of Disease.

[35]  C. Betzel,et al.  Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta‐mediated neurotoxicity , 2016, Journal of neurochemistry.

[36]  R. Nonno,et al.  A cationic tetrapyrrole inhibits toxic activities of the cellular prion protein , 2016, Scientific Reports.

[37]  P. Saftig,et al.  The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain , 2015, Progress in Neurobiology.

[38]  Seung Joong Kim,et al.  Prion Protein-Antibody Complexes Characterized by Chromatography-Coupled Small-Angle X-Ray Scattering. , 2015, Biophysical journal.

[39]  P. Herrlich,et al.  Inside-out Regulation of Ectodomain Cleavage of Cluster-of-Differentiation-44 (CD44) and of Neuregulin-1 Requires Substrate Dimerization*♦ , 2015, The Journal of Biological Chemistry.

[40]  P. Liberski,et al.  The sheddase ADAM10 is a potent modulator of prion disease , 2015, eLife.

[41]  S. Hornemann,et al.  Prion Infections and Anti-PrP Antibodies Trigger Converging Neurotoxic Pathways , 2015, PLoS pathogens.

[42]  F. Fahrenholz,et al.  Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin , 2014, Neurology.

[43]  C. Haigh,et al.  Neutron reflectometry studies define prion protein N-terminal peptide membrane binding. , 2014, Biophysical journal.

[44]  G. Legname,et al.  Prion Protein-Specific Antibodies-Development, Modes of Action and Therapeutics Application , 2014, Viruses.

[45]  J. Collinge,et al.  N-terminal Domain of Prion Protein Directs Its Oligomeric Association* , 2014, The Journal of Biological Chemistry.

[46]  X. Roucou,et al.  Aβ induces its own prion protein N-terminal fragment (PrPN1)–mediated neutralization in amorphous aggregates , 2014, Neurobiology of Aging.

[47]  M. Rowan,et al.  Peripheral Administration of a Humanized Anti-PrP Antibody Blocks Alzheimer's Disease Aβ Synaptotoxicity , 2014, The Journal of Neuroscience.

[48]  A. Aguzzi,et al.  Structural basis of prion inhibition by phenothiazine compounds. , 2014, Structure.

[49]  J. Steyaert,et al.  Recombinant Human Prion Protein Inhibits Prion Propagation in vitro , 2013, Scientific Reports.

[50]  Tiziana Sonati,et al.  The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein , 2013, Nature.

[51]  B. Chesebro,et al.  Unusual cerebral vascular prion protein amyloid distribution in scrapie-infected transgenic mice expressing anchorless prion protein , 2013, Acta neuropathologica communications.

[52]  H. Furuoka,et al.  Therapeutic effect of peripheral administration of an anti‐prion protein antibody on mice infected with prions , 2013, Microbiology and immunology.

[53]  M. Gobbi,et al.  An N-terminal Fragment of the Prion Protein Binds to Amyloid-β Oligomers and Inhibits Their Neurotoxicity in Vivo* , 2013, The Journal of Biological Chemistry.

[54]  K. Kuwata,et al.  Characterizing antiprion compounds based on their binding properties to prion proteins: Implications as medical chaperones , 2013, Protein science : a publication of the Protein Society.

[55]  A. Aguzzi,et al.  Prion Pathogenesis Is Faithfully Reproduced in Cerebellar Organotypic Slice Cultures , 2012, PLoS pathogens.

[56]  X. Roucou,et al.  PrPC Homodimerization Stimulates the Production of PrPC Cleaved Fragments PrPN1 and PrPC1 , 2012, The Journal of Neuroscience.

[57]  X. Roucou,et al.  The prion protein unstructured N‐terminal region is a broad‐spectrum molecular sensor with diverse and contrasting potential functions , 2011, Journal of neurochemistry.

[58]  B. de Strooper,et al.  Lack of a-disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo , 2011, Molecular Neurodegeneration.

[59]  S. Lindquist,et al.  The cellular prion protein mediates neurotoxic signalling of β‐sheet‐rich conformers independent of prion replication , 2011, The EMBO journal.

[60]  J. Collinge,et al.  Prion propagation and toxicity in vivo occur in two distinct mechanistic phases , 2011, Nature.

[61]  S. Strittmatter,et al.  Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an alzheimer's disease model mouse , 2010, BMC Neuroscience.

[62]  A. Aguzzi,et al.  Prion protein and Aβ-related synaptic toxicity impairment , 2010, EMBO Molecular Medicine.

[63]  B. de Strooper,et al.  Prion protein in Alzheimer's pathogenesis: a hot and controversial issue , 2010, EMBO molecular medicine.

[64]  A. Krüger,et al.  A Disintegrin and Metalloproteinase-10 (ADAM-10) Mediates DN30 Antibody-induced Shedding of the Met Surface Receptor* , 2010, The Journal of Biological Chemistry.

[65]  E. Kojro,et al.  Influence of ADAM10 on prion protein processing and scrapie infectiosity in vivo , 2009, Neurobiology of Disease.

[66]  N. Hooper,et al.  Role of ADAMs in the Ectodomain Shedding and Conformational Conversion of the Prion Protein* , 2009, The Journal of Biological Chemistry.

[67]  T. Wisniewski,et al.  Anti-PrP Mab 6D11 suppresses PrPSc replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo , 2009, Neurobiology of Disease.

[68]  D. Riesner,et al.  Complementarity determining regions of an anti-prion protein scFv fragment orchestrate conformation specificity and antiprion activity. , 2009, Molecular immunology.

[69]  S. Hornemann,et al.  The POM Monoclonals: A Comprehensive Set of Antibodies to Non-Overlapping Prion Protein Epitopes , 2008, PloS one.

[70]  Daniel Choquet,et al.  New Concepts in Synaptic Biology Derived from Single-Molecule Imaging , 2008, Neuron.

[71]  N. Ben-Tal,et al.  Stress‐protective signalling of prion protein is corrupted by scrapie prions , 2008, The EMBO journal.

[72]  J. Collinge,et al.  Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease , 2008, Proceedings of the National Academy of Sciences.

[73]  H. Furuoka,et al.  Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. , 2008, The Journal of general virology.

[74]  M. Sadowski,et al.  Clearance and prevention of prion infection in cell culture by anti‐PrP antibodies , 2006, The European journal of neuroscience.

[75]  F. Heppner,et al.  Paracrine Inhibition of Prion Propagation by Anti-PrP Single-Chain Fv Miniantibodies , 2005, Journal of Virology.

[76]  J. Solassol,et al.  Anti‐PrP antibodies block PrPSc replication in prion‐infected cell cultures by accelerating PrPC degradation , 2004, Journal of neurochemistry.

[77]  Christian Haass,et al.  Games Played by Rogue Proteins in Prion Disorders and Alzheimer's Disease , 2003, Science.

[78]  Sebastian Brandner,et al.  Depleting Neuronal PrP in Prion Infection Prevents Disease and Reverses Spongiosis , 2003, Science.

[79]  K. Fiebig,et al.  Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. , 2003, Journal of medicinal chemistry.

[80]  E. Wolf,et al.  Polyclonal Anti-PrP Auto-antibodies Induced with Dimeric PrP Interfere Efficiently with PrPSc Propagation in Prion-infected Cells* , 2003, The Journal of Biological Chemistry.

[81]  A. Aguzzi,et al.  Soluble Dimeric Prion Protein Binds PrPSc In Vivo and Antagonizes Prion Disease , 2003, Cell.

[82]  J. Collinge,et al.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease , 2003, Nature.

[83]  F. Checler,et al.  Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators , 2002, Trends in Neurosciences.

[84]  B. de Strooper,et al.  The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. , 2002, Human molecular genetics.

[85]  Pauline M. Rudd,et al.  Antibodies inhibit prion propagation and clear cell cultures of prion infectivity , 2001, Nature.

[86]  F E Cohen,et al.  Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[87]  M. Enari,et al.  Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[88]  K. Mikecz,et al.  Antibody-Induced Shedding of CD44 from Adherent Cells Is Linked to the Assembly of the Cytoskeleton1 , 2001, The Journal of Immunology.

[89]  W. Caughey,et al.  Porphyrin and phthalocyanine antiscrapie compounds. , 2000, Science.

[90]  E. Kojro,et al.  Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[91]  A. Aguzzi,et al.  Prion protein (PrP) with amino‐proximal deletions restoring susceptibility of PrP knockout mice to scrapie. , 1996, The EMBO journal.

[92]  A. Aguzzi,et al.  High Prion and PrPSc Levels but Delayed Onset of Disease in Scrapie-Inoculated Mice Heterozygous for a Disrupted PrP Gene , 1994, Molecular medicine.

[93]  A. Aguzzi,et al.  No propagation of prions in mice devoid of PrP , 1994, Cell.

[94]  S. Prusiner,et al.  Release of the cellular prion protein from cultured cells after loss of its glycoinositol phospholipid anchor. , 1993, Glycobiology.

[95]  D. Harris,et al.  A prion protein cycles between the cell surface and an endocytic compartment in cultured neuroblastoma cells. , 1993, The Journal of biological chemistry.

[96]  S. Prusiner,et al.  Molecular biology of prion diseases , 1991, Science.

[97]  S. Prusiner.  Novel proteinaceous infectious particles cause scrapie. , 1982, Science.

[98]  D. Westaway,et al.  Prion protein (PrPc) promotes beta-amyloid plaque formation. , 2005, Neurobiology of aging.

[99]  I. Ferrer,et al.  Prion protein expression in senile plaques in Alzheimer's disease , 2000, Acta Neuropathologica.